A team led by Stephen Jackson together with the UK’s Cancer Research Technology (Cancer Research UK’s commercial arm) and the University of Cambridge yesterday (August 25) announced the launch of MISSION Therapeutics, with Series A funding from a top venture capital syndicate.
The company has raised £6 million ($9.9 million) in Series A funding from a strong venture capital syndicate led by Sofinnova Partners, and comprising Imperial Innovations, SR One and Roche Venture Fund.
The new spin-out company will translate cutting-edge cell biology research on DNA repair from Prof Jackson’s laboratory at the Gurdon Institute, University of Cambridge, into drugs that will markedly improve the management of life-threatening diseases, particularly cancer. The company will be based at the Babraham Research Campus, Cambridge, UK.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze